Physician profile
Robert A Kloss
NPI 1649207770
$9,319.44
in general payments reported to CMS, 2019-2025
61 companies · $1,845 in 2025
The $1,845 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,822 · 2020: $381 · 2021: $141 · 2022: $558 · 2023: $2,021 · 2024: $2,552 · 2025: $1,845.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,268 · Education: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,267.92 |
| Education | $149.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $815.15 | 2019-2025 | Erleada, Rybrevant, Darzalex |
| Novartis Pharmaceuticals Corporation | $704.47 | 2019-2025 | |
| Abbvie INC. | $534.96 | 2023-2025 | |
| Celgene Corporation | $523.64 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Astrazeneca Pharmaceuticals LP | $465.50 | 2019-2025 | Tagrisso, Enhertu, Calquence |
| E.R. Squibb & Sons, L.L.C. | $375.30 | 2019-2025 | Opdivo, Opdualag |
| Pharmacyclics LLC, An Abbvie Company | $369.85 | 2019-2023 | Imbruvica, Epkinly |
| Pfizer INC. | $343.30 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $271.08 | 2019-2025 | Ninlaro, Fruzaqla, Alunbrig |
| Genentech USA, INC. | $267.53 | 2019-2025 | Tecentriq, Venclexta, Alecensa |
| Incyte Corporation | $252.04 | 2019-2025 | Monjuvi, Pemazyre, Jakafi |
| Amgen INC. | $238.09 | 2019-2023 | Kyprolis, Lumakras |
| Jazz Pharmaceuticals INC. | $217.75 | 2019-2025 | |
| Glaxosmithkline, LLC. | $214.22 | 2019-2025 | Ojjaara, Jemperli |
| Gilead Sciences, INC. | $208.58 | 2019-2025 | Trodelvy |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $193.73 | 2023-2024 | Krazati |
| Genzyme Corporation | $193.50 | 2019-2025 | |
| Array Biopharma INC | $192.47 | 2019-2025 | Mektovi, Braftovi, Lorbrena |
| Exelixis INC. | $188.41 | 2019-2025 | Cabometyx |
| Astellas Pharma US INC | $181.12 | 2023-2025 | Xospata, Padcev, Vyloy |
| Merck Sharp & Dohme LLC | $172.11 | 2019-2024 | Keytruda, Welireg |
| Seagen INC. | $162.00 | 2019-2023 | Adcetris, Tukysa |
| Eisai INC. | $155.46 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $145.66 | 2019-2025 | |
| Lilly USA, LLC | $136.54 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Daiichi Sankyo INC. | $131.94 | 2020-2025 | Enhertu |
| Sanofi-Aventis U.S. LLC | $112.57 | 2019-2020 | |
| Puma Biotechnology, INC. | $97.17 | 2019-2024 | |
| Sobi, INC | $96.87 | 2023-2025 | |
| Pharmaessentia USA Corporation | $89.92 | 2022-2024 | Besremi |
| Beigene USA, INC. | $88.27 | 2023-2024 | Brukinsa |
| Emd Serono, INC. | $78.31 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $76.04 | 2021-2025 | Libtayo |
| Rigel Pharmaceuticals, INC. | $71.37 | 2019-2025 | Rezlidhia, Gavreto, Tavalisse |
| Adc Therapeutics America, INC. | $66.02 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $65.09 | 2019 | |
| Coherus Oncology, INC. | $54.90 | 2023-2024 | |
| Ipsen Biopharmaceuticals, INC | $52.49 | 2019-2024 | Onivyde |
| Amag Pharmaceuticals, INC. | $50.90 | 2019 | |
| Taiho Oncology, INC. | $48.15 | 2019 | |
| Stemline Therapeutics INC. | $45.43 | 2023-2025 | Orserdu |
| Novocure INC. | $45.22 | 2019 | |
| Aveo Pharmaceuticals, INC. | $43.89 | 2024 | |
| Progenics Pharmaceuticals, INC. | $41.93 | 2023-2024 | Pylarify |
| Servier Pharmaceuticals LLC | $39.64 | 2024-2025 | |
| Tesaro, INC. | $37.91 | 2019 | |
| Karyopharm Therapeutics INC. | $37.48 | 2023 | Xpovio |
| Beone Medicines USA, INC. | $35.30 | 2025 | Brukinsa |
| Clovis Oncology, INC. | $34.74 | 2019 | |
| Myriad Genetic Laboratories, INC. | $32.61 | 2023-2024 | Precisetumor, Myrisk |
| Sirtex Medical INC | $32.44 | 2019 | |
| Sumitomo Pharma America, INC. | $28.56 | 2024 | Orgovyx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.55 | 2023 | Gilotrif |
| Deciphera Pharmaceuticals INC. | $24.30 | 2024 | Qinlock |
| Genmab U.S., INC. | $24.24 | 2024 | Tivdak |
| Medtronic, INC. | $23.44 | 2021 | |
| Dova Pharmaceuticals | $21.69 | 2019 | |
| Agios Pharmaceuticals, INC. | $15.90 | 2025 | Pyrukynd |
| Tempus Ai, INC | $14.35 | 2025 | Xt Cdx |
| Morphosys, US INC. | $13.35 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kloss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.